Disc Medicine (IRON) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Disc Medicine (IRON) over the past year, losing 1.3% versus a loss of 18.9%. Over five years, VRDN leads with a +63.7% price change compared with -14.2% for IRON. Disc Medicine is the larger company by market cap ($3.42 billion vs $3.40 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | VRDN |
|---|---|---|
| Share price | $75.14 | $29.96 |
| Market cap | $3.42B | $3.40B |
| 1-day change | -1.27% | -4.71% |
| YTD return | -5.38% | -3.73% |
| 1-year return | -18.86% | -1.25% |
| 5-year return | -14.22% | +63.72% |
| EPS (TTM) | $-6.34 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-212.18M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $99.50 | $34.29 |
| 52-week low | $40.00 | $13.18 |
| Distance from 52-week high | -24.48% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.94% | +42.72% |
| Average volume | 951.56K | 2.14M |
| Shares outstanding | 45.54M | 113.56M |
| Employees | 173 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRDN has outperformed IRON by 17.6 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
IRON vs VRDN FAQ
Which is bigger, Disc Medicine or Viridian Therapeutics?
Disc Medicine (IRON) is larger, with a market capitalization of $3.42B compared with $3.40B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, IRON or VRDN?
VRDN returned -1.25% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.